On April 7, it was reported that a questionnaire recently released by JD Health involved key areas such as new drug research and development, clinical trials and patient recruitment, which has aroused widespread concern and speculation in the industry, and some people speculate that JD may plan to enter the field of drug development.
In response, JD Health clarified the company's business positioning, emphasizing that drug research and development is not included in the current or future business layout, and made it clear that the company will not enter this industry.
Regarding this research activity, JD Health further clarified its purpose. The initiative is part of a service initiative to raise consumer awareness of drug use and food safety and raise public awareness of related safety issues.
According to the financial report data released a few days ago, in 2023, JD Health has achieved significant performance growth. The company's total revenue reached 53.5 billion yuan, an increase of 14.5% year-on-year, net profit climbed to 4.14 billion yuan, an increase of 58.1% over the previous year, and the active consumer group expanded to 172 million, an increase of 11.7% year-on-year.
From the perspective of platform development, JD Health has successfully attracted more than 50,000 third-party merchants to join, with a year-on-year growth rate of more than 100%, which shows its remarkable achievements in expanding the number of cooperative merchants.
At the same time, JD Pharmacy launched more than 30 original first-class innovative drugs online, and 1.3 million new products in the nutrition and health care category. In addition, the average number of online medical consultations exceeded 450,000 per day, indicating that the company has also made significant progress in providing online medical services.